Result: Other NRTI-associated mutations detected included T69A/N/S (n=21), V75L, V118I and T215A/I.
New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
PMID: 21417755
2011
AIDS research and human retroviruses
Abstract: L10I (4.5%), V118I/IV (17.4%), and K103R/KR (10.0%) were commonly observed mutations, but do not confer any drug resistance to PIs, NRTIs, and NNRTIs.
[Prevalence of primary antiretroviral resistance among HIV infected patients in Chile].
Abstract: Point mutations for non nucleoside reverse transcriptase inhibitors (NNRTI) were detected in 4.1% of cases (K103N in 1 patient, V179D in 2 patients), for nucleoside reverse transcriptase inhibitors (NRTI) in 8.1% of cases (T215S in 1 patient, V118I in 4 patients, M41L in 1 patient) and for protease inhibitors (PI) in 1.3% of cases.
Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
Abstract: The GPOvir-failure cases had not only known stavudine-, lamivudine- and nevirapine-resistant mutations, but also V118I, G196E, and H221Y.
Comparison of genotypic resistance mutations in treatment-naive HIV type 1-infected patients in Korea and China.
PMID: 20156103
2010
AIDS research and human retroviruses
Abstract: Although no major TDR was observed within the study population, some resistance-associated mutations in the reverse transcriptase region were observed (V118I 9.2%, V179D 7.9%).
HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
Abstract: Naive patients had accessory mutations in the PR gene [A71T (1/6), L10V (2/6), L10I (3/6)] and in the RT gene [V118I (2/6), V179D (1/6), V106I (1/6), K101Q (1/6), H221Y (1/6)].
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Table: V118I
Figure: Phylogenetic analysis of plasma HIV variants isolated from a representative subject (Subject 2) whose baseline HIV-1 RNA was 5.30 log10 copies/mL and whose baseline (pre-therapy) population genotype was wild-type and who at failure had an HIV-1 RNA of 2.87 log10 copies/mL and a population genotype of K65R + S68N/S + Y115F/Y + V118I.
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
Result: One individual (0.8%) had a K65R mutation, denoting probable reduced sensitivity to tenofovir and abacavir, and 3 had the V118I mutation (2.5%).
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.
Result: Seven of the 104 samples (6.7%) had a mutation associated with NRTI resistance (one mutation in each sample: M41L (n = 2), E44D (n = 3), V118V/I (n = 1), K219K/R (n = 1)), and one sample had a mutation associated with NNRTI resistance (E138A).
Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients.
Discussion: For instance, V118I has been identified in 2% of treatment-naive patients as one of strain-specific polymorphisms, but more frequently observed in RTI-treated patients.
HIV mutation literature information.
PMID: 
2011
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT